Abstract: This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells.
Type:
Grant
Filed:
June 11, 2012
Date of Patent:
November 10, 2015
Assignee:
NODALITY, INC.
Inventors:
Wendy J. Fantl, Santosh K. Putta, Omar D. Perez, Helen L. Francis-Lang, Aileen C. Cohen
Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.
Type:
Grant
Filed:
March 30, 2012
Date of Patent:
December 30, 2014
Assignee:
Medy-Tox Inc.
Inventors:
Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Hack Woo Kim, Sung Bum Kim, Seung Hwan Baek